Advancements in Gene Therapy for Ophthalmic Disorders: Ocugen’s Clinical Program Updates

Time: 11:30 am
day: Day Two 12th

Details:

• Advancing the transition from preclinical to clinical stages and a gene-agnostic trial approach for diverse patient recruitment
• Optimizing the enrolment progress and Phase 3 developments for Leber Congenital Amaurosis (LCA)
• Uncovering the safety profile and efficacy data for Dry Age-Related Macular Degeneration (AMD) program

Speakers:

Arun Upadhyay Arun Upadhyay, PhD, Chief Scientific Officer, and Head of Research, Development and Medical, drives Ocugen’s innovation and product development. He leads science and operations, creating Read more